1. Montani, D, Günther, S, Dorfmüller, P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis 2013; 8: 97.
Google Scholar | Crossref | Medline | ISI2. Eddahibi, S, Morrell, N, d'Ortho, MP, et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J 2002; 20: 1559–1572.
Google Scholar | Crossref | Medline3. Levinson, AT, Klinger, JR. Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2011; 5: 419e430.
Google Scholar | SAGE Journals4. McGoon, MD, Benza, RL, Escribano-Subias, P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: D51–D59.
Google Scholar | Crossref | Medline | ISI5. Galiè, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.
Google Scholar | Crossref | Medline | ISI6. Simonneau, G, Souza, R (Chair) (Eds.), PH haemodynamic definitions and clinical classifications and characteristics of specific PAH subgroups. In: 6th World Symposium on pulmonary hypertension, Nice, France, 27 February–1 March February 2018.
Google Scholar7. Burks, M, Stickel, S, Galiè, N. Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs 2018; 18: 249–257.
Google Scholar | Crossref | Medline8. Hayashi, T, Matsumoto, S, Hosokawa, A., et al. Rivaroxaban combined with spironolactone attenuates cardiovascular remodeling due to hypoxia in pulmonary arterial hypertension. Eur Heart J 2018; 39: 2501.
Google Scholar | Crossref9. Bendtzen, K, Hansen, PR, Rieneck, K. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor‐alpha and interferon‐gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134: 151–158.
Google Scholar | Crossref | Medline | ISI10. Macdonald, JE, Kennedy, N, Struthers, AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765–770.
Google Scholar | Crossref | Medline | ISI11. Budhiraja, R, Tuder, RM, Hassoun, PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159–165.
Google Scholar | Crossref | Medline | ISI12. Hassoun, PM, Mouthon, L, Barbera, JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10–S19.
Google Scholar | Crossref | Medline | ISI13. Galiè, N, Brundage, BH, Ghofrani, HA, et al. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.
Google Scholar | Crossref | Medline | ISI14. Simonneau, G, Barst, RJ, Galie, N, et al. Treprostinil Study Group . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
Google Scholar | Crossref | Medline | ISI15. Tapson, VF, Torres, F, Kermeen, F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142: 1383–1390.
Google Scholar | Crossref | Medline | ISI16. Tapson, VF, Jing, ZC, Xu, KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144: 952–958.
Google Scholar | Crossref | Medline | ISI17. Jing, ZC, Parikh, K, Pulido, T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127: 624–633.
Google Scholar | Crossref | Medline | ISI18. Takeda, M, Tatsumi, T, Matsunaga, S, et al. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 2007; 30: 427–437.
Google Scholar | Crossref | Medline19. Zannad, F, Alla, F, Dousset, B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102: 2700–2706.
Google Scholar | Crossref | Medline | ISI20. Tsutamoto, T, Wada, A, Maeda, K, et al . Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–1233.
Google Scholar | Crossref | Medline | ISI21. Safdar, Z, Tamez, E, Chan, W, et al . Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail 2014; 2: 412–421.
Google Scholar | Crossref | Medline22. Safdar Z, Tamez E, Frost A, Guffey D, Minard CG, et al. Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension. Int J Cardiovasc Res 2015; 4: 2. doi:10.4172/2324-8602.1000198.
Google Scholar23. Safdar, Z, Frost, A, Basant, A, et al. Spironolactone in pulmonary arterial hypertension: results of a cross-over study. Pulm Circ 2020; 10: 2045894019898030.
Google Scholar | SAGE Journals | ISI24. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902–907.
Google Scholar | Crossref | Medline | ISI25. Pitt, B, Zannad, F, Remme, WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
Google Scholar | Crossref | Medline | ISI26. Juurlink, DN, Mamdani, MM, Lee, DS, et al. Rates of hyperkalemia after publication of the randomized Aldactone evaluation study. N Engl J Med 2004; 351: 543–551.
Google Scholar | Crossref | Medline | ISI27. Safdar, Z, Thakur, A, Singh, S, et al. Circulating aldosterone levels and disease severity in pulmonary arterial hypertension. J Pulm Respir Med 2015; 5: 295.
Google Scholar | Crossref | Medline28. Blalock, SE, Matulevicius, S, Mitchell, LC. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010; 16: 121–127.
Google Scholar | Crossref | Medline | ISI29. Ferreira, JP. High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure. Cor et Vasa 2014; 56: e463–e470.
Google Scholar | Crossref30. Lahm T, Hess E, Barón AE, et al. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. Chest 2021; 159: 1586–1597. doi: 10.1016/j.chest.2020.09.258.
Google Scholar